Metformin versus metformin plus rosiglitazone in women with polycystic ovary syndrome

Chinese Medical Journal

Volumn 124, Issue 5, 2011, Pages 714-718

  Liao, Lin ^a   Tian, Yong Jie ^a   Zhao, Jia Jun ^a   Xin, Ying ^a   Xing, Hai Yang ^a   Dong, Jian Jun ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

Metformin; Polycystic ovary syndrome; Rosiglitazone

Indexed keywords

CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUTEINIZING HORMONE; METFORMIN; ROSIGLITAZONE; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY MASS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; EPIGASTRIC DISCOMFORT; FEMALE; FOLLOW UP; HUMAN; HYPOGLYCEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MONOTHERAPY; OVARY POLYCYSTIC DISEASE; PREGNANCY; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LUTEINIZING HORMONE; METFORMIN; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; THIAZOLIDINEDIONES; TRIGLYCERIDES; YOUNG ADULT;

EID: 79952544573     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.05.015     Document Type: Article

References (23)

1. Fleming R, Hopkinson ZE, Wallace AM, Wallace AM, Greer IA, Satter N. Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial. J Clin Endocrinol Metab 2002; 87: 569-574.
2. Harbome L, Fleming R, Lyall H, Noman J, Sattar N. Descriptive review of the evidence for the use of metformin in polycystic ovary syndrome. Lancet 2003; 361: 1894-1901.
3. Kjotrod SB, von During V, Carlsen SM. Metformin treatment before IVF/ICSI in women with polycystic ovary syndrome; a prospective, randomized, double blind study. Hum Reprod 2004; 19: 1315-1322.
4. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004; 19: 41-47.
5. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus: provisional report of a WHO consultation. Diabet Med 1998; 15: 539-553.
6. Mansfield R, Galea R, Brincat M, Hold D, Mason H. Metformin has direct effects on human ovarian teroidogenesis. Fertil Steril 2003; 79: 956-962.
7. La Marca A, Artensio AC, Stabile G, Volpe A. Metformin treatment of PCOS during adolescence and the reproductive period. Eur J Obstet Gynecol Reprod Biol 2005; 121: 3-7.
8. Kolodziejezyk B, Duleba AJ, Spaczynski RZ, Pawelczyk L. Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovary syndrome. Fertil Steril 2000; 73: 1149-1154.
9. Yilmaz M, Bukan N, Ayvaz G, Karakoc A, Cakir N, Ayhan M, et al. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Hum Reprod 2005; 20: 3333-3340.
10. Johnson K. Rosiglitazone may induce ovulation in metformin-resistant PCOS. OB GYN News. January 1, 2002.
11. Ghazeeri G, Kutteh WH, Bryer-Ash M, Haas D, Ke RW. Effect of rosiglitazone on spontaneous and clomiphene citrate-induced ovulation in women with polycystic ovary syndrome. Fertil Steril 2003; 79: 562-566.
12. Froment P, Touraine P. Thiazolidinediones and fertility in Polycystic Ovary Syndrome (PCOS). PPAR Res 2006; 73986: 1-8.
13. Legro RS, Zaino RJ, Demers LM, Kunselman AR, Gnatuk CL, Williams NI, et al. The effects of metformin and rosiglitazone, alone and in combination, on the ovary and endometrium in polycystic ovary syndrome. Am J Obstet Gynecol 2007; 196: 402-410.
14. Mitkov M, Pehlivanov B, Terzieva D. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Eur J Obstet Gynecol Reprod Biol 2006; 126: 402-410.
15. Feng SY, Yang DZ, Kuang JQ, Xie MQ. Comparison of clinical effects between flumamine and roglitazone on abnormal metabolism in women with PCOS. Chin J Practical Obstet Gynecol (Chin) 2006; 22: 227-230.
16. Baillargeon JP, Jakubowicz DJ, Iuorno MJ, Jakubowicz S, Nestler JE. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril 2004; 82: 893-903.
17. Inoue S, Zimmet P, Caterson I, Chen CM, Ikeda Y, Khalid AK, et al. The Asia-Pacific perspective: Redefining obesity and its treatment. February 2000, Published by Health Communications Australia Pty Limited on behalf of the Steering Committee. ISBN 0-9577082-1-1. Page 17-19.
18. Wollen N, Bailey CJ. Inhibition of hepatic gluconeogenesis by metformin. Synergism with insulin. Biochem Pharmacol 1988; 37: 4353-4358.
19. Nolan JJ, Ludvik B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994; 331: 1188-1193.
20. Nawaz FZ, Khalid R, Naru T, Rizvi J. Does continuous use of metformin throughout pregnancy improve pregnancy outcomes in women with polycystic ovarian syndrome? Obstet Gynaecol Res 2008; 34: 832-837.
21. Yaris F, Yaris E, Kadioglu M, Ulku C, Kesim M, Kalyoncu NI. Normal pregnancy outcome following inadvertent exposure to rosiglitazone, gliclazide, and atorvastatin in a diabetic and hypertensive woman. Reprod Toxicol 2004; 18: 619-621.
22. Kalyoncu NI, Yaris F, Ulku C, Kadioglu M, Kesim M, Unsal M, et al. A case of rosiglitazone exposure in the second trimester of pregnancy. Reprod Toxicol 2005; 19: 563-564.
23. Dunaif A. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome-a reappraisal. Nat Clin Pract Endocrinol Metab 2008; 4: 272-283.